

## Resistance or Defiance? The FDA and the 11th Circuit Spar Over Statute on Orphan Drug Statutory Exclusivity

February 23, 2023

### ATTORNEYS

Landmon, Chad

Chad Landmon

*Clinical Leader*

### PRACTICE AREAS

FDA

Intellectual Property

Axinn partner Chad Landmon authored the *Clinical Leader* article, "Resistance or Defiance? The FDA and the 11th Circuit Spar Over Statute on Orphan Drug Statutory Exclusivity."

[Click here to access the article.](#)